David Bourdon, Ph.D Senior R&D Manager and Immunoassay Strategy Lead, Biosciences Division, Thermo Fisher Scientific
Yorba Linda, Ca (PRWEB) May 02, 2017
Thermo Fisher Scientific, the worldwide leader in life science tools for researchers, is unveiling an affordable new platform for the next generation of high-sensitivity, ready-to-use immunoassays in a new webinar. Featuring serum compatible, TaqMan™ based Proximity Ligation Assay (PLA) and Siteclick™ antibody labeling technologies, this new assay combines the analyte specificity of high affinity antibody-antigen binding with the signal detection and amplification of real-time PCR.
Early detection of protein biomarkers is critical to the study of human disease, such as cancer, neurobiology, inflammation, autoimmunity, etc. Basic research scientists, as well as translational investigators seek sensitive protein quantitation tools that provide low-level detection of disease relevant protein analytes.
The Enzyme-Linked ImmunoSorbant Assay (ELISA) first developed in the 1970s and slightly improved upon over the years, is still considered the gold standard for specific protein quantitation, yet large sample consumption, limited sensitivity, and laborious workflows leave room for improvement and new innovation.
With this new platform from Thermo Fisher, not only do these assays allow measurement of low expressing proteins that we may not have otherwise been able to detect, but it’s also an easy method to now verify gene expression at a protein level. During this webinar, attendees will learn how to achieve greater sensitivity and dynamic range than traditional methods, as well as other key benefits.
The speaker for this presentation is Dr. David Bourdon, the senior research and development manager and immunoassay strategy lead at Thermo Fisher Scientific in the Biosciences Division.
Bourdon completed his doctorate of pharmacology at the University of Missouri-Columbia School of Medicine, followed by his post-doctorate fellowship at the University of North Carolina at Chapel Hill School of Medicine. Joining Thermo Fisher Scientific in 2009, Bourdon now serves as the senior manager and immunoassay strategy lead focusing on next-gen immunoassay platform development.
LabRoots will host the webinar June 6, 2017, commencing at 8:00 a.m. PT, 11:00 a.m. ET. To read more about this event, learn about the P.A.C.E. and Florida Continuing Education credits offered, or to register for free, click here.
ABOUT THERMO FISHER SCIENTIFIC
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit http://www.thermofisher.com.
ABOUT LABROOTS
LabRoots is the leading scientific social networking website and producer of educational virtual events and webinars. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.